Richter Joel E
Department of Medicine, Temple University School of Medicine, 3401, North Broad Street, 801 Parkinson Pavilion, Philadelphia, PA 19140, USA.
Expert Rev Gastroenterol Hepatol. 2008 Jun;2(3):435-45. doi: 10.1586/17474124.2.3.435.
Achalasia cannot be cured. Instead, our goal is to relieve symptoms of dysphagia and regurgitation, improve esophageal emptying and prevent the development of megaesophagus. The most definitive therapies are pneumatic dilation and surgical myotomy. The overall success of grade pneumatic dilation is 78%, with women and older patients performing best. Laparoscopic myotomy has an overall success rate of 85%, but can be complicated by the sequelae of severe acid reflux disease. Young patients, especially men, are the best candidates for surgical myotomy. There are no prospective, randomized studies comparing these two procedures. Botulinum toxin injections into the esophagus and smooth muscle relaxants are reserved for older patients or those with major comorbid illnesses. Some patients with end-stage achalasia will require esophagectomy.
贲门失弛缓症无法治愈。相反,我们的目标是缓解吞咽困难和反流症状,改善食管排空并预防巨食管的发展。最确切的治疗方法是气囊扩张术和手术肌切开术。气囊扩张术的总体成功率为78%,女性和老年患者效果最佳。腹腔镜肌切开术的总体成功率为85%,但可能会并发严重酸反流疾病的后遗症。年轻患者,尤其是男性,是手术肌切开术的最佳候选人。目前尚无比较这两种手术的前瞻性随机研究。向食管注射肉毒杆菌毒素和平滑肌松弛剂适用于老年患者或患有严重合并症的患者。一些终末期贲门失弛缓症患者需要进行食管切除术。